By Dr. Steven Papish Sacituzumab- Govitecan (Trodelvy) is a new treatment for refractory triple negative breast cancer.  Last month, the company released the following summary to oncologists:   “On 4/22/2020, the FDA approved Trodelvy for the treatment of patients with metastatic triple negative breast cancer. Patients had evidence of progressive disease on at least 2…

Read More